Table 4 Quality of life determinants in bivariate and multivariate analysis

Cutaneous adverse events

−1.88 [−5.73; 1.98] (0.339)

Type of treatment

 Conventional chemotherapy

1

 Targeted therapy

−0.98 [−4.76; 2.80] (0.610)

Type of tumor

 Breast

1

 Digestive

1.63 [−3.20; 6.47] (0.505)

 Lung

−2.14 [−8.19; 3.91] (0.485)

 Gynecological

−2.21 [−11.5; 7.11] (0.640)

 Urological

0.18 [−6.92; 7.28] (0.961)

 Other

0.60 [−7.98; 9.18] (0.891)

Tumor stage

 2

1

1

 3

−11.4 [−19.4; −3.42] (0.005)

−10.18 [−17.38; 2.99] (0.006)

 4

−12.0 [−18.7; −5.29] (0.001)

−11.59 [−17.66; −5.52] (< 0.0001)

Number of treatment cycles

 1–5

  6–10

  11–15

  16–20

  More than 20

1

5.75 [0.92; 10.58] (0.020)

4.82 [−1.95; 11.60] (0.162)

1.11 [−7.66; 9.88] (0.804)

2.55 [−3.89; 9.00] (0.436)

Performance status (ECOG)

  0

  1

  2

  3

1

−14.37 [−22.41; −6.32] (0.001)

−22.47 [−31.36; −13.57] (< 0.0001)

−36.0 [−51.60; −20.40] (< 0.0001)

1

−14.63 [−22.26; −7.01] (< 0.0001]

−21.28 [−29.72; 12.85] (< 0.0001)

−34.11 [−48.91; −19.31] (< 0.0001)

Performance status (ECOG)

 0

1

1

 1

−14.37 [−22.41; −6.32] (0.001)

−14.63 [−22.26; −7.01] (< 0.0001]

 2

−22.47 [−31.36; −13.57] (< 0.0001)

−21.28 [−29.72; 12.85] (< 0.0001)

 3

−36.0 [−51.60; −20.40] (< 0.0001)

−34.11 [−48.91; −19.31] (< 0.0001)

Previous treatment lines

 1

 2

−0.76 [−6.54; 5.03] (0.796)

 More than 2

−6.96 [−15.07; 1.15] (0.092)

Concomitant disorders

−2.35 [−6.38; 1.68] (0.252)

Age

−0.05 [−0.21; 0.10] (0.502)

Female sex

−4.62 [−8.34; −0.89] (0.015)

−4.01 [−7.40; −0.63] (0.020)